Founded in 2015 by Dr. Tyler Jacks, head of the Koch Institute at MIT, Bill Haney, a longtime tech entrepreneur and investor, and Dr. David Raulet, one of the world's leading experts in Natural Killer (NK) cell biology, Dragonfly Therapeutics develops novel first-in-class therapeutics targeted at Natural Killer cells and other cells of the innate immune system.
Dragonfly's therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses, and are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies – such as T cell treatments.
Our founders and Scientific Advisory Board are major figures in cancer biology and immunology, and launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. Dr. Tyler Jacks is a highly decorated scientist, head of the Koch Institute for Integrative Cancer Research at MIT — broadly considered the world's leading basic cancer research institution, with more than 780 scientists and engineers – and has spent the last three decades carrying out cutting-edge studies in cancer genetics and cancer immunology. Dr. Jacks' research on the potential of NK cells to enhance and direct other immunotherapies led him to team up with Dr. David Raulet, one of the world's leading researchers on Natural Killer cells, whose internationally recognized discoveries on the role of NK cell inhibitory and activating receptors in destroying tumors provide a critical foundation for Dragonfly's approach to cancer immunotherapy. Dr. Raulet directs a major research laboratory at UC, Berkeley focused on breakthrough research on NK cells and T cells, and how they can be used for therapy or prevention of disease.
Our mission is to revolutionize cancer treatment by inventing therapies that harness the body's immune system for vastly improved patient outcomes.
Dr. Tyler Jacks is a highly decorated scientist, the head of the Koch Institute for Integrative Cancer Research at MIT — broadly considered the world's leading basic cancer research institution, with more than 780 scientists and engineers, and co-chair of the White House's Cancer "Moonshot" Blue Ribbon Panel.
Dr. Jacks directs a major research laboratory at the Koch Institute, carrying out cutting-edge studies in cancer genetics and cancer immunology.
Dr. Jacks received his B.A. in Biology from Harvard in 1983, and Ph.D. from UC San Francisco, where he trained with Nobel Laureate Harold Varmus.
Co-founder Dr. David Raulet is the Esther and Wendy Schekman Chair in Cancer Biology at UC,Berkeley, and one of the world's leading researchers on Natural Killer cells.
Dr. Raulet directs a major research laboratory at UC, Berkeley, focused on breakthrough research on how Natural Killer cells and T cells recognize and destroy cancer cells, and how this information can be used for therapy or prevention of disease.
Dr. Raulet received his Ph.D. in Biology from the Massachusetts Institute of Technology.
An inventor and entrepreneur, Bill Haney started his first company as a college freshman, inventing and building air pollution control systems for power plants. Since then he has started or helped start more than a dozen technology companies.
Bill was a founding member of the national environmental advisory board for the US Environmental Protection Agency, the President's Circle for the National Academy of Sciences, has won a Humanitarian Award from Harvard Medical School, an Achievement Award from the ACLU, a Genesis Award and serves or has served on boards for Harvard, MIT, State and Federal Government agencies, the World Wildlife Fund, the World Resources Institute, and the NRDC.
Bill holds a BA from Harvard College and was a Kennedy School Fellow from 1997-2001.